Mylan to distribute Sovaldi and Harvoni in India

US generics major Mylan (Nasdaq: MYL) said today that its Indian subsidiary has entered into an agreement with Gilead Sciences (Nasdaq: GILD), under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni(ledipasvir 90mg/sofosbuvir 400mg tablets) for the treatment of chronic hepatitis C, in India.

As Gilead's exclusive branded medicine distribution partner, Mylan expects to begin distribution of Sovaldi in India in the second quarter of 2015. Sovaldi received regulatory approval in India in January 2015 – the first country in Asia to approve the medicine. Financial terms of the accord are not disclosed.

Mylan president Rajiv Malik said: "Hepatitis C is a growing public health concern, particularly in developing countries such as India where access to high quality, effective and affordable treatment remains a challenge. Mylan is proud to partner with Gilead to expand access to Sovaldi and Harvoni, life-saving medications that offer an improvement in the standard of care for the 12 million hepatitis C patients in India.”